Published in J Bone Miner Res on January 01, 2001
Acid phosphatases. Mol Pathol (2002) 1.55
Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care. Can Fam Physician (2011) 1.28
Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol (2011) 0.92
Bone disease in primary hyperparathyrodism. Ther Adv Musculoskelet Dis (2012) 0.89
Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol (2010) 0.84
Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int (2016) 0.84
Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract (2010) 0.79
Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int (2014) 0.78
Bone turnover markers in primary hyperparathyroidism. J Clin Densitom (2013) 0.76
Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review. Front Endocrinol (Lausanne) (2017) 0.75
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A (2001) 2.56
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol (2000) 2.47
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
The time course of a hypercalcaemic crisis in acute primary hyperparathyroidism. Lancet (1984) 2.21
Site-specific effects of strength training on bone structure and geometry of ultradistal radius in postmenopausal women. J Bone Miner Res (1999) 2.05
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int (2005) 1.80
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res (2000) 1.80
Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab (2013) 1.77
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care (2001) 1.74
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int (2006) 1.54
Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int (2015) 1.46
Bone loss in response to long-term glucocorticoid therapy. Bone Miner (1990) 1.44
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab (1999) 1.43
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) (2001) 1.40
Vertebral morphometry by X-ray absorptiometry before and after liver transplant: a cross-sectional study. Eur J Gastroenterol Hepatol (2001) 1.39
Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int (2003) 1.36
Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif Tissue Int (2003) 1.29
Cytochrome oxidase assembly in yeast requires the product of COX11, a homolog of the P. denitrificans protein encoded by ORF3. EMBO J (1990) 1.28
Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int (2012) 1.25
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res (2002) 1.22
Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int (2009) 1.13
Radioimmunoassay of 1,25-dihydroxy vitamin D2: studies on the metabolism of vitamin D2 in man. Clin Endocrinol (Oxf) (1983) 1.13
Measurement of the WW + WZ production cross section using the lepton + jets final state at CDF II. Phys Rev Lett (2010) 1.12
First observation of the decay Bs0-->Ds-Ds+ and measurement of its branching ratio. Phys Rev Lett (2008) 1.11
Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis (2008) 1.09
Hypomagnesaemia: studies of parathyroid hormone secretion and function. Clin Endocrinol (Oxf) (1984) 1.08
Measurement of sigma chi c2 B(chi c2-->J/psi gamma)/sigma chi c1 B(chi c1 -->J/psi gamma) in pp collisions at square root s=1.96 TeV. Phys Rev Lett (2007) 1.07
Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The Pro.V.A. (PROgetto Veneto Anziani) study. Clin Exp Rheumatol (2010) 1.07
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis (2004) 1.06
Direct measurement of the W production charge asymmetry in pp collisions at square root s=1.96 TeV. Phys Rev Lett (2009) 1.04
Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int (2007) 1.03
Search for long-lived massive charged particles in 1.96 TeV pp collisions. Phys Rev Lett (2009) 1.03
Prevalence and correlates of vertebral fractures in adults with cystic fibrosis. Bone (2004) 1.02
[Incidence and socioeconomic burden of hip fractures in Italy]. Reumatismo (2005) 1.02
Mineral metabolism and bone mineral content in rheumatoid arthritis. Effect of corticosteroids. Clin Exp Rheumatol (1985) 1.02
Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol (1985) 1.02
Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis (2007) 1.01
Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res (2000) 1.01
Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res (2003) 1.01
Helicobacter pylori VacA cytotoxin associated with the bacteria increases epithelial permeability independently of its vacuolating activity. Microbiology (1999) 1.00
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int (2013) 1.00
Observation of Bs(0)-Bs(0) oscillations. Phys Rev Lett (2006) 1.00
Relation between adiponectin and bone mineral density in elderly post-menopausal women: role of body composition, leptin, insulin resistance, and dehydroepiandrosterone sulfate. J Endocrinol Invest (2008) 1.00
Self-report of difficulty in performing functional activities identifies a broad range of disability in old age. J Am Geriatr Soc (1996) 0.99
Bone density and skeletal metabolism are altered in idiopathic hypercalciuria. Clin Nephrol (1998) 0.98
Acute effects of moderate dietary protein restriction in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Am J Clin Nutr (1999) 0.97
[Guidelines on prevention and treatment of vitamin D deficiency. Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)]. Reumatismo (2011) 0.97
Search for large extra dimensions in final states containing one photon or jet and large missing transverse energy produced in pp collisions at square root[s]=1.96 TeV. Phys Rev Lett (2008) 0.97
Polarizations of J/psi and psi(2S) mesons produced in pp collisions at square root s = 1.96 TeV. Phys Rev Lett (2007) 0.96
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int (2001) 0.96
Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int (2007) 0.95
Hypophosphatemic oncogenic osteomalacia: report of three new cases. Tumori (1988) 0.95
Measurement of the top-quark mass in all-hadronic decays in pp collisions at CDF II. Phys Rev Lett (2007) 0.95
Age-related cortical bone loss at the metacarpal. Calcif Tissue Int (1997) 0.95
Relationship among VDR (BsmI and FokI), COLIA1, and CTR polymorphisms with bone mass, bone turnover markers, and sex hormones in men. Calcif Tissue Int (2002) 0.95
The superoxide dismutase activity of desulfoferrodoxin from Desulfovibrio desulfuricans ATCC 27774. Eur J Biochem (1999) 0.95
Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis (1997) 0.94
Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res (1994) 0.94
Epidemiology of osteoporosis: a study of fracture mortality in Italy. Calcif Tissue Int (1990) 0.94
Association of CTR and COLIA1 alleles with BMD values in peri- and postmenopausal women. Calcif Tissue Int (2000) 0.93
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int (2008) 0.93
The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest (2009) 0.93
Evaluating energy efficiency of site-specific tillage in maize in NE Italy. Bioresour Technol (2008) 0.93
Redox-linked proton translocation in the b-c1 complex from beef-heart mitochondria reconstituted into phospholipid vesicles. Studies with chemical modifiers of amino acid residues. Eur J Biochem (1983) 0.92
Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int (1986) 0.92
Search for a fermiophobic Higgs boson decaying into diphotons in pp[over] collisions at sqrt[s] = 1.96 TeV. Phys Rev Lett (2009) 0.92
The effects of menopause and estrogen replacement therapy on the renal handling of calcium. Osteoporos Int (1992) 0.92
Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin (2007) 0.91
Familial benign hypercalcaemia. Study of a large family. Q J Med (1983) 0.91
First measurement of the b-jet cross section in events with a W boson in pp collisions at square root(s) = 1.96 TeV. Phys Rev Lett (2010) 0.91
The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner (1991) 0.90
Search for Z' --> e+ e- using dielectron mass and angular distribution. Phys Rev Lett (2006) 0.90
Definition of a population-specific DXA reference standard in Italian women: the Densitometric Italian Normative Study (DINS). Osteoporos Int (2003) 0.89
Measurements of the angular distributions in the decays B→K(*)μ(+)μ(-) at CDF. Phys Rev Lett (2012) 0.88
Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Horm Res (2000) 0.88
Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature. Br J Cancer (2013) 0.88